Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Traws Pharma (TRAW) Equity Average (2016 - 2025)

Traws Pharma (TRAW) has disclosed Equity Average for 14 consecutive years, with $6.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average rose 111.91% to $6.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.4 million, a 111.91% increase, with the full-year FY2024 number at -$10.5 million, down 153.76% from a year prior.
  • Equity Average was $6.4 million for Q3 2025 at Traws Pharma, down from $7.1 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $47.9 million in Q4 2021 to a low of -$53.8 million in Q3 2024.
  • A 5-year average of $13.8 million and a median of $20.9 million in 2023 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: skyrocketed 420.86% in 2021, then tumbled 421.87% in 2024.
  • Traws Pharma's Equity Average stood at $47.9 million in 2021, then plummeted by 35.61% to $30.8 million in 2022, then tumbled by 59.16% to $12.6 million in 2023, then tumbled by 233.64% to -$16.8 million in 2024, then surged by 138.04% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Equity Average are $6.4 million (Q3 2025), $7.1 million (Q2 2025), and -$12.8 million (Q1 2025).